EUVIMEDEUVIMED entdecken
Crossref

The importance of ever-evolving phase 1 trials in oncology

Andreas Domen, Pieterjan Vanclooster, Laure-Anne Teuwen, Bernd Dekeyser, Timon Vandamme, Hans Prenen

Academia Oncology · 18.03.2026 · 3 (1)

DOI: 10.20935/acadonco8203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Academia Oncology, online erschienen am 18.03.2026. Verfasst von Andreas Domen und 5 weiteren Autor:innen. Die Arbeit nennt 74 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phase 1 clinical trials are a critical step in oncology drug development. Historically, these first-in-human trials focused on dose–toxicity profiling in heterogeneous populations. With the emergence of novel anticancer therapies, trial design has shifted toward model-based and adaptive dose-escalation designs, improving dose optimization, and now incorporates biomarker-driven patient selection and multiple objectives, including early efficacy assessment, which accelerates drug development. Hence, phase 1 clinical trials have undergone substantial transformation over recent decades, with a marked impact on response rates and phase 1 units that conduct these trials. By transforming early-stage drug discovery and target identification as well as predicting drug efficacy and toxicity, the implementation of artificial intelligence into early-phase cancer research will further accelerate the discovery of novel anticancer drugs and significantly transform today’s phase 1 trials, ultimately resulting in an increase in phase 1 clinical trials in the near future. In this narrative review, we address the importance of clinical phase 1 trials for oncology drug development, highlight their continuous evolution over the past decades to date, and discuss how this affects phase 1 units and their investigators, as well as exploring the impact of artificial intelligence on phase 1 trials in the coming years.

Zitieren

APA

Domen, A., Vanclooster, P., Teuwen, L., Dekeyser, B., Vandamme, T., & Prenen, H. (2026). The importance of ever-evolving phase 1 trials in oncology. Academia Oncology, 3(1). https://doi.org/10.20935/acadonco8203

Vancouver

Domen A, Vanclooster P, Teuwen L, Dekeyser B, Vandamme T, Prenen H. The importance of ever-evolving phase 1 trials in oncology. Academia Oncology. 2026;3(1). doi:10.20935/acadonco8203

BibTeX
@article{Domen2026,
  author = {Domen, Andreas and Vanclooster, Pieterjan and Teuwen, Laure-Anne and Dekeyser, Bernd and Vandamme, Timon and Prenen, Hans},
  title = {The importance of ever-evolving phase 1 trials in oncology},
  journal = {Academia Oncology},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.20935/acadonco8203}
}
Kostenlos starten →